Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug hopes to ease rare lung disease

NCT ID NCT07318597

First seen Jan 07, 2026 · Last updated May 19, 2026 · Updated 23 times

Summary

This study tests an experimental drug called REGN13335 for people with pulmonary arterial hypertension (PAH), a condition that makes it hard for the heart to pump blood to the lungs. About 99 adults with mild to moderate symptoms who are already on standard PAH medications will receive either REGN13335 or a placebo. The goal is to see if the drug safely lowers pressure in the lung arteries and improves heart function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION PAH are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Imperial College Healthcare NHS Trust, Hammersmith Hospital

    RECRUITING

    London, W12 0HS, United Kingdom

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • University of Colorado Denver

    RECRUITING

    Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.